FDA to Launch New Board to Improve Monitoring of Supply Chain
The FDA’s Center for Drug Evaluation and Research (CDER) is setting up a new board to strengthen pharmaceutical supply-chain monitoring in the wake of COVID-19-related drug shortages.
The Pharmaceutical Supply Chain Governance Board, which will get under way next month, is tasked with coordinating all CDER supply-chain initiatives and providing guidance and fixes for major supply-chain issues.
This will include overseeing the ongoing development for the agency’s existing Drug Supply-Chain System used to monitor shortages, which was first implemented last fall.
Jacqueline Corrigan-Curay, CDER’s principal deputy center director, will chair the new board.